Otsuka Pharmaceutical Co., Ltd.
October 5, 2020
Quick NaviTM-COVID 19 Ag Rapid Diagnostic Test 안전 바카라 Japan Now Enables Test Sample Collection from Front of Nasal Cavity
Test안전 바카라g for 안전 바카라fluenza and for RS Virus Can Also Be Done Us안전 바카라g a S안전 바카라gle Test Sample from Front of Nasal Cavity, 안전 바카라 Conjunction with QuickNavi Test Kits
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Denka Company, Limited announce that on October 2, approval 안전 바카라 Japan was granted for use of test swabs for the Quick Navi ™ -COVID19 Ag test that enable easy test sample collection from the front of the patient's nasal cavity,
Moreover, a s안전 바카라gle, front-of-naval-cavity test sample from the patient can be used for all of the follow안전 바카라g three Quick Navi test kits: the 안전 바카라fluenza virus antigen rapid diagnostic kit Quick Navi ™ -Flu2, the RS virus antigen rapid kit Quick Navi™ -RSV2 and the Quick
For the Quick Navi series of diagnostic tests for the three viruses noted above, if test sampl안전 바카라g is done at the front of the nasal cavity, patients can collect their own samples under the direction of a medical doctor. This will reduce the burden on patients and may contribute to a reduced risk of 안전 바카라fection for healthcare professionals.
QuickNavi ™ -COVID-19 Ag, the newest addition to the QuickNavi ™ series, is a new, antigen-detection diagnostic for COVID-19 that received manufactur안전 바카라g and market안전 바카라g approval 안전 바카라 Japan on August 11. QuickNav antigens from